Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2019. Module: SNOMED CT core
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
3769833013 | Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3769834019 | Product containing precisely carbidopa anhydrous (as carbidopa) 31.25 milligram and entacapone 200 milligram and levodopa 125 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
4578131000052112 | entakapon 200 milligram, karbidopa, vattenfritt (som karbidopa) 31,25 milligram och levodopa 125 milligram, oral tablett | sv | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT Sweden NRC maintained module (core metadata concept) |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Is a | Product containing only carbidopa and entacapone and levodopa in oral dose form (medicinal product form) | true | Inferred relationship | Some | ||
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has precise active ingredient | Entacapone (substance) | true | Inferred relationship | Some | 1 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | har täljarvärde som visar styrka | 200 (qualifier value) | false | Inferred relationship | Some | 1 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | har nämnarvärde som visar styrka | 1 (qualifier value) | false | Inferred relationship | Some | 3 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | har nämnarvärde som visar styrka | 1 (qualifier value) | false | Inferred relationship | Some | 2 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 3 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | räkning av bas i aktiv ingrediens | 3 (qualifier value) | false | Inferred relationship | Some | ||
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 3 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | har nämnarvärde som visar styrka | 1 (qualifier value) | false | Inferred relationship | Some | 1 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has manufactured dose form | Oral tablet | true | Inferred relationship | Some | ||
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has basis of strength substance (attribute) | Entacapone (substance) | true | Inferred relationship | Some | 1 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | har täljarvärde som visar styrka | 31.25 (qualifier value) | false | Inferred relationship | Some | 3 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | har täljarvärde som visar styrka | 125 (qualifier value) | false | Inferred relationship | Some | 2 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has precise active ingredient | Levodopa (substance) | true | Inferred relationship | Some | 2 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has precise active ingredient | Carbidopa | true | Inferred relationship | Some | 3 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has basis of strength substance (attribute) | Levodopa (substance) | true | Inferred relationship | Some | 2 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Has basis of strength substance (attribute) | Carbidopa anhydrous | true | Inferred relationship | Some | 3 | |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet | Plays role | Antiparkinson therapeutic role | true | Inferred relationship | Some |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets